USES SKYRIZI is a prescription medicine used to treat adults with: moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV …

Nov 11, 2025 · Skyrizi (risankizumab) is an injection used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. Includes indications, doses, interactions, side effects and more.

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) …

Jul 23, 2024 · As a treatment for ulcerative colitis, Skyrizi works by fighting the inflammation that can lead to symptoms of the disease.

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This approval …

SKYRIZI® is indicated for the treatment of moderately to severely active ulcerative colitis in adults. See Important Safety and Prescribing Information.

May 8, 2025 · What is the best medicine for ulcerative colitis? The treatment options for ulcerative colitis vary based on the disease’s severity and can be categorized into six main types: conventional …

Jun 20, 2024 · The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works by blocking the …

For patients with moderate to severe ulcerative colitis, these findings offer hope and a new treatment option. Risankizumab belongs to a newer class of medications targeting IL-23, which is different from …

MONTREAL, QC, March 4, 2025 – AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely …